Face-Off: DF/MGH/HCC vs. YALE : Episode 5
Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial
A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.
EP: 1.Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate
EP: 2.Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC
EP: 3.Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study
EP: 4.KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC
Now Viewing
EP: 5.Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial
EP: 6.Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial
EP: 7.Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study
EP: 8.Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
EP: 9.Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC
EP: 10.Face-Off: Award Presentations and Event Conclusion
Recent Videos
Related Content
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
